AbbVie (ABBV) Hisse Özeti
Araştırmaya dayalı bir biyofarmasötik şirketi olan AbbVie Inc. dünya çapında ilaç ve terapilerin araştırılması ve geliştirilmesi, üretimi, ticarileştirilmesi ve satışı ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 4/6 |
Ödüller
Risk Analizi
ABBV Community Fair Values
Create NarrativeSee what 449 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbbVie Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$251.06 |
| 52 Haftanın En Yüksek Seviyesi | US$255.99 |
| 52 Haftanın En Düşük Seviyesi | US$184.63 |
| Beta | 0.31 |
| 1 Aylık Değişim | 17.91% |
| 3 Aylık Değişim | 20.22% |
| 1 Yıllık Değişim | 31.62% |
| 3 Yıllık Değişim | 82.43% |
| 5 Yıllık Değişim | 115.04% |
| Halka arzdan bu yana değişim | 617.31% |
Son Haberler & Güncellemeler
Recent updates
ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline
Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.AbbVie: Immunology Cash Flow Funds Oncology Expansion
Summary I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients. Meanwhile, Venclexta generated $770 million in revenue for AbbVie in Q1, up 15.8% year-over-year and 8.5% QoQ. Also, inthis article, you will know why the superiority of UCB's Bimzelx over Skyriziin the Phase 3 BE BOLD study doesn't threaten the sales growth of AbbVie's IL-23 inhibitor. Read the full article on Seeking AlphaAbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution
AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025
AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.Hissedar Getirileri
| ABBV | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 6.9% | 3.7% | 1.6% |
| 1Y | 31.6% | 37.9% | 21.1% |
Getiri vs. Endüstri: ABBV geçen yıl % 37.9 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: ABBV geçen yıl % 21.1 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: ABBV son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ABBV 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2012 | 57,000 | Robert Michael | www.abbvie.com |
Araştırmaya dayalı bir biyofarmasötik şirketi olan AbbVie Inc. dünya çapında ilaç ve tedavilerin araştırılması ve geliştirilmesi, üretimi, ticarileştirilmesi ve satışı ile uğraşmaktadır. Şirket, otoimmün hastalıkları tedavi etmek için Skyrizi; enflamatuar hastalıkları tedavi etmek için Rinvoq; kan kanserli yetişkin hastaların tedavisi için Imbruvica; kan kanserlerini tedavi etmek için Venclexta; çeşitli kanserleri tedavi etmek için Elahere; ve lenfoma tedavisi için Epkinly; ve akciğer kanseri tedavisi için Emrelis sunmaktadır. Ayrıca yüz enjektablları, plastik ve rejeneratif tıp, vücut şekillendirme ve cilt bakım ürünleri; glabellar çizgiler, kaz ayakları, alın çizgileri ve platizma bantlarının tedavisi için botox Cosmetic; şakaklar, göz altı, yanaklar, çene, dudaklar ve alt yüzdeki hacim kaybını tedavi etmek için Juvederm Collection sunmaktadır; Şizofreni, bipolar bozukluk ve depresif bozukluğu tedavi etmek için Vraylar; Parkinson hastalığını tedavi etmek için Duodopa; migreni tedavi etmek için Ubrelvy; epizodik ve kronik migren için Qulipta; ve motor dalgalanmaların tedavisi için Vyalev'in yanı sıra kronik migren, aşırı aktif mesane, spastisite, servikal distoni ve diğer durumları tedavi etmek için Botox Therapeutic.
AbbVie Inc. Temel Bilgiler Özeti
| ABBV temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$444.60b |
| Kazançlar(TTM) | US$3.60b |
| Gelir(TTM) | US$62.82b |
ABBV aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ABBV gelir tablosu (TTM) | |
|---|---|
| Gelir | US$62.82b |
| Gelir Maliyeti | US$17.57b |
| Brüt Kâr | US$45.25b |
| Diğer Giderler | US$41.65b |
| Kazançlar | US$3.60b |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Jul 31, 2026
| Hisse başına kazanç (EPS) | 2.03 |
| Brüt Marj | 72.03% |
| Net Kâr Marjı | 5.72% |
| Borç/Özkaynak Oranı | -1,102.7% |
ABBV uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
ABBV güvenilir bir temettü ödüyor mu?
ABBV temettü geçmişine ve kıyaslamalara bakın| AbbVie temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Jul 15 2026 |
| Temettü Ödeme Tarihi | Aug 14 2026 |
| Eski temettüye kadar geçen günler | 12 days |
| Temettü ödeme tarihine kadar geçen günler | 42 days |
ABBV güvenilir bir temettü ödüyor mu?
ABBV temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/01 19:40 |
| Gün Sonu Hisse Fiyatı | 2026/07/01 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
AbbVie Inc. 51 Bu analistlerden 24, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |